All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MPN Advocates Network.
The mpn Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mpn Hub cannot guarantee the accuracy of translated content. The mpn and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The MPN Hub is an independent medical education platform, sponsored by AOP Health and GSK, and supported through an educational grant from Bristol Myers Squibb and Incyte. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View mpn content recommended for you
Ruben A. MesaDuring the First Annual Texas Virtual MPN Workshop, the MPN Hub spoke to our Steering Committee member, Ruben A. Mesa, UT Health San Antonio, San Antonio, US, about whether it is a good idea to use JAK inhibitors (JAKi) in early, or asymptomatic, myelofibrosis (MF).
Should we treat asymptomatic (‘early’) myelofibrosis with JAKi?
JAKi were originally used in more advanced cases of MF and showed positive results in these patients. Now the use of JAKi, specifically ruxolitinib, is being applied to low risk patients.